retatrutide triple agonist weight loss trial 🚨 BREAKING: Shows “Bariatric-Level” in Phase 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Triple Agonism Based Therapies for

Eberhardy SR, Farnham PJ

TREK-1 knockout mice show increased seizure susceptibility to kainate and ischemia-induced epileptic events

In a randomized trial in patients with obesity and cardiometabolic diseases, at 56 weeks, the mean weight loss was: Patients in the active treatment groups also had significant improvements in cardiovascular and metabolic risk factors such as waist circumference, systolic blood pressure, and total cholesterol/high-density lipoprotein cholesterol ratio

GLP-1 Receptor Agonists: Are They a Cure for Everything

Independent studies conducted by Birsoy and Shen have identified SLC25A39 as the key mitochondrial transporter for importing GSH into mitochondria